Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company, presented first-in-human data for LFD-200, a subcutaneously administered antibody-drug conjugate (ADC) delivering a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 in London. The Phase 1 study in healthy participants demonstrated that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a key marker for systemic glucocorticoid toxicity.
The findings, presented in a poster session, highlight the potential of LFD-200 to treat autoimmune and inflammatory disorders like rheumatoid arthritis (RA) while avoiding the side effects associated with systemic glucocorticoids. Glucocorticoids are effective anti-inflammatory agents but often cause serious adverse effects such as adrenal suppression, osteoporosis, and metabolic disturbances when used systemically. By targeting delivery to immune cells, LFD-200 aims to maximize therapeutic benefit while minimizing systemic exposure.
According to the company, the Phase 1 study is now enrolling patients with moderate to severe rheumatoid arthritis, with data expected by the end of 2026. The initial healthy participant data provide a foundation for advancing LFD-200 into patient populations, where its safety and efficacy will be further evaluated.
Lifordi is leveraging the success of ADCs, a technology widely used in oncology, to develop treatments for immune-mediated diseases. The company's proprietary platform enables conjugation of diverse payloads, including antisense oligonucleotides, siRNA, and small molecules, to antibodies for targeted delivery. LFD-200 is the lead candidate, and its favorable profile in healthy volunteers supports continued development.
"These Phase 1 results are an important milestone for Lifordi and for the field of autoimmune disease treatment," said a company representative. "The ability to deliver a potent glucocorticoid directly to target cells without suppressing cortisol could offer a new therapeutic option for patients with rheumatoid arthritis and other inflammatory conditions."
Lifordi is backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, reflecting confidence in its approach. The company is committed to changing the treatment landscape for immune and inflammatory diseases. For more information, visit www.lifordi.com.
The presentation at EULAR 2026 marks a key step in demonstrating the clinical potential of ADC technology beyond oncology. If successful, LFD-200 could become a first-in-class treatment for RA, offering patients an effective therapy with reduced systemic side effects. The upcoming patient data will be critical in determining the drug's future and its impact on the standard of care.
